166 related articles for article (PubMed ID: 34312001)
21. Nadir CA-125 serum levels during neoadjuvant chemotherapy and no residual tumor at interval debulking surgery predict prognosis in advanced stage ovarian cancer.
Nakamura K; Kitahara Y; Nishimura T; Yamashita S; Kigure K; Ito I; Kanuma T
World J Surg Oncol; 2020 Aug; 18(1):200. PubMed ID: 32791996
[TBL] [Abstract][Full Text] [Related]
22. Infection, thrombosis, and oncologic outcome after interval debulking surgery: Does perioperative blood transfusion matter?
Manning-Geist BL; Alimena S; Del Carmen MG; Goodman A; Clark RM; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
Gynecol Oncol; 2019 Apr; 153(1):63-67. PubMed ID: 30635213
[TBL] [Abstract][Full Text] [Related]
23. Risk factors for septic adverse events and their impact on survival in advanced ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking surgery.
Son JH; Lee JH; Jung JA; Kong TW; Paek J; Chang SJ; Ryu HS
Gynecol Oncol; 2018 Oct; 151(1):32-38. PubMed ID: 30122310
[TBL] [Abstract][Full Text] [Related]
24. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
Fotopoulou C; duBois A; Karavas AN; Trappe R; Aminossadati B; Schmalfeldt B; Pfisterer J; Sehouli J;
J Clin Oncol; 2008 Jun; 26(16):2683-9. PubMed ID: 18509180
[TBL] [Abstract][Full Text] [Related]
25. Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: A systematic review and meta-analysis.
Machida H; Tokunaga H; Matsuo K; Matsumura N; Kobayashi Y; Tabata T; Kaneuchi M; Nagase S; Mikami M
Eur J Surg Oncol; 2020 May; 46(5):868-875. PubMed ID: 31818526
[TBL] [Abstract][Full Text] [Related]
26. Venous thromboembolism in advanced ovarian cancer patients undergoing frontline adjuvant chemotherapy.
Pant A; Liu D; Schink J; Lurain J
Int J Gynecol Cancer; 2014 Jul; 24(6):997-1002. PubMed ID: 24905613
[TBL] [Abstract][Full Text] [Related]
27. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer.
Rauh-Hain JA; Rodriguez N; Growdon WB; Goodman AK; Boruta DM; Horowitz NS; del Carmen MG; Schorge JO
Ann Surg Oncol; 2012 Mar; 19(3):959-65. PubMed ID: 21994038
[TBL] [Abstract][Full Text] [Related]
28. Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study.
Fagö-Olsen CL; Ottesen B; Kehlet H; Antonsen SL; Christensen IJ; Markauskas A; Mosgaard BJ; Ottosen C; Soegaard CH; Soegaard-Andersen E; Hoegdall C
Gynecol Oncol; 2014 Feb; 132(2):292-8. PubMed ID: 24321400
[TBL] [Abstract][Full Text] [Related]
29. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
[No Abstract] [Full Text] [Related]
30. Risk of venous thromboembolism for ovarian cancer patients during first-line therapy after implementation of an Enhanced Recovery After Surgery (ERAS) protocol.
Li S; Bercow AS; Falzone M; Kalyanaraman R; Worley MJ; Feltmate CM; Pelletier A; Elias KM
Gynecol Oncol; 2021 Aug; 162(2):353-359. PubMed ID: 34092412
[TBL] [Abstract][Full Text] [Related]
31. Venous thromboembolism risk in patients receiving neoadjuvant chemotherapy for bladder cancer.
Garas SN; McAlpine K; Ross J; Carrier M; Bossé D; Yachnin D; Mallick R; Cagiannos I; Morash C; Breau RH; Lavallée LT
Urol Oncol; 2022 Aug; 40(8):381.e1-381.e7. PubMed ID: 35581123
[TBL] [Abstract][Full Text] [Related]
32. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
Jiang R; Zhu J; Kim JW; Liu J; Kato K; Kim HS; Zhang Y; Zhang P; Zhu T; Aoki D; Yu A; Chen X; Wang X; Zhu D; Zhang W; Jia H; Shi T; Gao W; Yin S; Feng Y; Xiang L; Okamoto A; Zang R
J Gynecol Oncol; 2020 Sep; 31(5):e86. PubMed ID: 32808504
[TBL] [Abstract][Full Text] [Related]
33. Risk of Venous Thromboembolism for Patients with Pancreatic Ductal Adenocarcinoma Undergoing Preoperative Chemotherapy Followed by Surgical Resection.
Boone BA; Zenati MS; Rieser C; Hamad A; Al-Abbas A; Zureikat AH; Hogg ME; Neal MD; Zeh HJ
Ann Surg Oncol; 2019 May; 26(5):1503-1511. PubMed ID: 30652227
[TBL] [Abstract][Full Text] [Related]
34. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.
Luo Y; Lee M; Kim HS; Chung HH; Song YS
Medicine (Baltimore); 2016 Sep; 95(36):e4797. PubMed ID: 27603388
[TBL] [Abstract][Full Text] [Related]
35. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
Fagotti A; Ferrandina G; Vizzielli G; Fanfani F; Gallotta V; Chiantera V; Costantini B; Margariti PA; Gueli Alletti S; Cosentino F; Tortorella L; Scambia G
Eur J Cancer; 2016 May; 59():22-33. PubMed ID: 26998845
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of glycemic parameters on venous thromboembolism risk prediction in gastrointestinal cancer.
Guadagni F; Riondino S; Formica V; Del Monte G; Morelli AM; Lucchetti J; Spila A; D'Alessandro R; Della-Morte D; Ferroni P; Roselli M
World J Gastroenterol; 2017 Jul; 23(28):5187-5195. PubMed ID: 28811713
[TBL] [Abstract][Full Text] [Related]
37. Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Sia TY; Manning-Geist BL; Ehmann S; Lavery JA; Luardo C; Praiss A; Iasonos A; Sonoda Y; Grisham RN; Liu YL; Broach V; Zivanovic O; Long Roche K; Gardner GJ; Chi DS
Gynecol Oncol; 2023 Sep; 176():69-75. PubMed ID: 37454565
[TBL] [Abstract][Full Text] [Related]
38. Venous thromboembolism in women with ovarian cancer undergoing neoadjuvant chemotherapy prior to cytoreductive surgery: A retrospective study.
Oxley SG; Achampong YA; Sambandan N; Hughes DJ; Thomas M; Lockley M; Olaitan A
Acta Obstet Gynecol Scand; 2021 Nov; 100(11):2091-2096. PubMed ID: 34486103
[TBL] [Abstract][Full Text] [Related]
39. Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study.
Gueli Alletti S; Bottoni C; Fanfani F; Gallotta V; Chiantera V; Costantini B; Cosentino F; Ercoli A; Scambia G; Fagotti A
Am J Obstet Gynecol; 2016 Apr; 214(4):503.e1-503.e6. PubMed ID: 26529370
[TBL] [Abstract][Full Text] [Related]
40. Retrospective Evaluation of Thromboembolism Risk in Ovarian Cancer Patients Treated with Bevacizumab.
Kuk A; Magnowska M; Suchy W; Swierczynska J; Zaborowski MP; Gaca M; Nowak-Markwitz E
Target Oncol; 2017 Aug; 12(4):495-503. PubMed ID: 28580507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]